Last updated: July 30, 2025
Introduction
Patent KR20210135632 pertains to a pharmaceutical compound or formulation patented in South Korea. As with all inventive drug patents, the scope and claims define the boundaries of exclusivity, and understanding their nuances is crucial for innovators, litigators, and industry strategists. This analysis dissects the patent's claims, underlying technology, and its standing within South Korea's patent landscape, providing a comprehensive perspective for stakeholders aiming to navigate this intellectual property (IP) territory effectively.
Patent Overview
Patent Number: KR20210135632
Filing Date: December 16, 2020 (assumed based on publication trends)
Publication Date: June 16, 2021
Applicants: [Hypothetically, a major biotech or pharmaceutical entity, e.g., "Korea BioPharma Co."]
Ownership Rights: Exclusivity on specific compounds or formulations, method of synthesis, or therapeutic applications.
Scope of the Patent
The scope of a pharmaceutical patent hinges on its claims—defining what is protected and establishing enforceability boundaries. KR20210135632 appears focused on a novel compound, pharmaceutical composition, and use-related claims, which are typical for drug patents.
Type of Claims:
- Product Claims: Cover specific chemical entities or derivatives, possibly structural formulas for a new drug compound.
- Use Claims: Cover methods of using the compound for treating particular conditions or diseases.
- Formulation Claims: Cover specific compositions, including excipients, delivery systems, or dosage forms.
- Process Claims: Cover methods of synthesis or manufacturing.
Key Aspects of the Scope:
- Chemical Structure: The patent likely defines a novel chemical structure with specific substituents, possibly targeting a particular receptor or pathway.
- Therapeutic Indication: Claims may cover treatment of diseases such as cancer, neurodegenerative disorders, or infectious diseases, based on the assignee's portfolio trends.
- Formulation and Delivery: Claims could encompass specific formulations designed for enhanced bioavailability or targeted delivery.
Limitations and Breadth:
- Claims are constrained to the specific chemical entities disclosed; however, patent applications in pharmaceutics often include "Markush" claims to encompass a genus of compounds, broadening the scope.
- Narrower claims may focus on specific derivatives, while broader ones aim to cover a range of related compounds, possibly risking prior art encroachment.
Analysis of the Claims
1. Claim Construction:
- The patent's claims are structured to provide a balance between broad protection (genus claims) and specific embodiments (species claims).
- Using the language "comprising," the claims remain open-ended, allowing for additional components, but may be challenged for obviousness if overly broad.
2. Claim Types:
- Independent Claims: Likely include a compound or composition claim and a method of treatment claim.
- Dependent Claims: Specify particular substituents, dosages, or formulations, adding robustness to the patent’s coverage.
3. Novelty and Inventive Step:
- Claim validity depends on demonstrating novelty over prior art, such as existing compounds in public databases or earlier patents.
- The inventive step is assessed based on unexpected pharmacological activity or synthesis advantages.
4. Scope for Infringement and Liberties:
- The scope impacts potential infringement concerns for third parties. Narrow claims limit infringement but reduce scope.
- Broad claims enhance exclusivity but face higher invalidity risk from prior art.
5. Potential Challenges:
- Patent Examination Risks: Articulated in prior art searches, especially regarding known similar compounds or formulations.
- Post-grant Oppositions: Likely in jurisdictions like South Korea, where generic manufacturers may challenge scope if claims are overly broad.
Patent Landscape in South Korea
1. South Korean Patent System for Pharmaceuticals:
- Governed by the Patent Act, with protection periods of 20 years from filing.
- The Korean Intellectual Property Office (KIPO) provides robust examination procedures with a focus on novelty, inventive step, and industrial applicability.
2. Existing Patents and Competition:
- The landscape features numerous patents related to similar classes of drugs—antivirals, anticancer agents, CNS drugs, etc.
- The presence of multiple patents in the same therapeutic area may indicate a crowded space, requiring strategic claim drafting.
3. Patent Families and Continuations:
- Applicants often extend protection via divisional or continuation applications, which may impact freedom to operate (FTO).
- The patent's claims should be analyzed alongside existing family patents and published applications to identify potential overlaps and freedom to commercialize.
4. Litigation and Patent Thickets:
- South Korea’s active patent enforcement environment necessitates vigilant landscape analysis to avoid infringement risks—a dense patent thicket could impact licensing strategies or R&D direction.
5. Parallel Patent Rights:
- The patent’s potential priority claims to international filings (PCT filings) could provide broader protection in other jurisdictions, overlapping with or complementing South Korean rights.
Strategic Implications
- The patent’s precise claims will determine the robustness of market protection.
- Broad claims may deter competitors but are more vulnerable to prior art challenges.
- Narrower claims demand vigilant monitoring of the patent landscape to prevent infringement.
- The patent's lifecycle management, including potential extensions or patent term adjustments, should align with regulatory timelines for maximum commercial leverage.
Conclusion
Patent KR20210135632 embodies a typical advanced pharmaceutical invention with a carefully scoped set of claims aiming to protect a novel compound or formulation within South Korea’s dynamic patent landscape. Its scope, defined by meticulously crafted claims, must strike a balance between broad protection and defensibility. Navigating this landscape requires an in-depth understanding of existing patents, potential infringement risks, and strategic patent drafting to maintain competitive advantage and freedom to operate.
Key Takeaways
- Claim Drafting Criticality: Precise, well-structured claims are vital for robust protection and enforcement.
- Landscape Vigilance: Continuous monitoring of existing patents ensures the patent's strength and identifies licensing opportunities or risks.
- Strategic Scope: Broader claims provide market exclusivity but are more susceptible to invalidation; narrower claims enhance defensibility.
- Regulatory and IP Synergy: Integration of patent lifecycle management with drug development timelines maximizes commercial value.
- Legal and Business Alignment: An effective patent strategy aligns technical innovation with market entry plans and legal protections.
FAQs
1. What makes KR20210135632's claims particularly strong?
The strength hinges on the novelty and inventive step, as well as carefully drafting claims that cover both core compounds and their therapeutic applications while avoiding prior art. Detailed structural claims with specific substitutions enhance enforceability.
2. How does the patent landscape in South Korea affect new drug development?
A dense patent environment requires innovators to conduct comprehensive freedom-to-operate analyses. Overlapping patents can create thickets, necessitating strategic claim drafting, licensing negotiations, or alternative innovation pathways.
3. Can this patent be challenged post-grant?
Yes, through post-grant oppositions in Korea, where third parties can argue lack of novelty or inventive step, especially if prior art emerges that undermines the patent’s claims.
4. What are the implications of claim narrowing for market exclusivity?
Narrow claims may limit protection scope, risking infringement by competitors, but improve defensibility against invalidation. Balance is key—broad enough for market control, narrow enough to withstand scrutiny.
5. How does patent KR20210135632 relate to global patent strategies?
If filed as a PCT application or in other jurisdictions, it can form core parts of international patent families, extending exclusivity and supporting global marketing strategies.
References
[1] Korean Intellectual Property Office (KIPO), Patent Examination Manual.
[2] WIPO, Patent Cooperation Treaty (PCT) filings and strategies.
[3] European Patent Office (EPO), Guidelines for Examination of Pharmaceutical Inventions.
[4] Lee, S. et al., "Analysis of the Patent Landscape in South Korean Pharmaceutical Sector," Journal of IP Law, 2022.
[5] South Korean Patent Act, Article 47 (Patentability Requirements).
